---
title: 'Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed
  ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase
  IIIb trial'
date: '2023-10-05'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37797734/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231006181031&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: In ovarian cancer patients previously treated with one
  prior PARP inhibitor and at least two lines of platinum-based chemotherapy, maintenance
  olaparib rechallenge provided a statistically significant, albeit modest, PFS improvement
  over placebo in both the BRCA-mutated and non-BRCA-mutated cohorts, with a proportion
  of patients in the maintenance olaparib rechallenge arm of both cohorts remaining
  progression free at 1 ...'
disable_comments: true
---
CONCLUSIONS: In ovarian cancer patients previously treated with one prior PARP inhibitor and at least two lines of platinum-based chemotherapy, maintenance olaparib rechallenge provided a statistically significant, albeit modest, PFS improvement over placebo in both the BRCA-mutated and non-BRCA-mutated cohorts, with a proportion of patients in the maintenance olaparib rechallenge arm of both cohorts remaining progression free at 1 ...